Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 416Lymphoma 406Lymphoma, Non-Hodgkin 344Leukemia, Lymphocytic, Chronic, B-Cell 313Lymphoma, Follicular 301Lymphoma, Mantle-Cell 226Lymphoma, B-Cell, Marginal Zone 161Lymphoma, B-Cell 112Leukemia 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 82Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 33Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 24Leukemia, Myeloid, Acute 24Multiple Myeloma 21Dendritic Cell Sarcoma, Interdigitating 19Intraocular Lymphoma 17Leukemia, Prolymphocytic 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Hematologic Neoplasms 13Lymphoproliferative Disorders 12Leukemia, Hairy Cell 11Leukemia, B-Cell 11Hematologic Diseases 11

Interventions

Rituximab 2CT-P10 2prednylidene 1pembrolizumab 1deltacortene 1Vincristine 1Prednisone 1Lenalidomide 1Doxorubicin 1Cyclophosphamide 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Composite Lymphoma × Rituximab × Lymphoid × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

NCT02541565 2020-10-14

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

University of Washington

Phase 1 Completed
30 enrolled 9 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡